IMC Calls for Pharmacare Reform to Ensure Access to Innovative Medicines and Protect Personalized Care
Ottawa, March 21, 2025 – With the imminent announcement of a federal election, Canadians have an opportunity to reflect on the […]
Pharmacare
All Canadians should have access to the medicines they need, and most already have coverage through existing public and private drug plans. Why is Ottawa replacing coverage that works instead of focusing on filling the gaps?
One-Size-Fits-All Doesn’t Work for Canadians’ Drug Coverage
97% of Canadians are already eligible for drug coverage.
By switching to a one-size-fits-all system, Canadians who rely on cutting-edge treatments risk losing access to the broad range of medicines and therapies that private plans can provide. While the Pharmacare Act presents an important opportunity to broaden access and close gaps in coverage, the program’s design will be critical in determining its success; it could either expand coverage or risk leaving many Canadians without adequate support.
How Can We Safeguard Canadians’ Access to Innovative Medicines?
The Government of Canada must work with the provinces to ensure Canadians have access to the coverage that fits their needs. We encourage provincial governments to actively engage in negotiations with the federal government, ensuring that solutions reflect the specific health needs of their populations. This approach will ensure that pharmacare funds are used to address real, unmet needs rather than duplicating existing services or altering service coverage available to Canadians.
Join the Conversation
Share our infographics on social media to spread the word about the importance of a Pharmacare program that works for Canadians and protects existing coverage and access to innovative medicines.
Download the infographics above and post on your social channels.
Stay Informed
Read the latest news and updates on Pharmacare.
News
Statement from Innovative Medicines Canada on the Committee of Experts to make recommendations on National Pharmacare
We are disappointed to see that, once again, the government has excluded the pharmaceutical industry’s voice from important discussions on […]
Statement from Innovative Medicines Canada on the passage of Bill C-64, the Pharmacare Act
With the passage of the Pharmacare Act, Innovative Medicines Canada remains concerned that the pharmacare program as outlined in the […]
